Journal Article

DZNE-2026-00639

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Estimation of positron emission tomography amyloid load and related biomarkers in Alzheimer's disease using evoked potential tomography EEG: development and internal validation in a cross-sectional cohort.

Rauchmann, B.-S. (First author)DZNE* ; Hamet, J. ; Lai, J. ; Kafi, H. ; Rexwinkle, J. ; Brendel, M.DZNE* ; Franzmeier, N. ; Kurz, C. ; Pogarell, O. ; Levin, J.DZNE* ; Höglinger, G.DZNE* ; Perneczky, R. (Last author)DZNE*

2026
BioMed Central London

This record in other databases:    

Please use a persistent id in citations: doi:10.1186/s13195-026-02076-7

Abstract: Dementia affects over 50 million individuals globally, predominantly due to Alzheimer's disease (AD). Effective early detection and intervention remain clinical challenges, as there is a lack of unified, portable solutions to assess multiple biomarkers.We evaluated Evoked Potential Tomography (EPT), an EEG-based method using a novel visual evoked potential protocol. An automated pipeline for EEG preprocessing, ERP extraction, feature selection, optimization, and regression modeling was developed to estimate key AD biomarkers: PET-amyloid standardized uptake value ratio (SUVR), CSF phosphorylated tau (p-tau181), Free and Cued Selective Reminding Test (FCSRT), and Mini-Mental State Examination (MMSE) scores.Regression models using ERP features from dementia participants demonstrated strong correlations (r = 0.8-0.94, p < 0.01) between predicted and true PET-amyloid SUVR, p-tau181, FCSRT, and MMSE values. In an independent external cohort, PET-amyloid SUVR predictions remained significantly associated with true values (r = 0.60, p < 0.01).Despite limitations, these preliminary results support EPT's potential as a sensitive and non-invasive method for estimating AD-related biomarkers in a clinically enriched AD cohort. Further validation studies are ongoing.

Keyword(s): Humans (MeSH) ; Alzheimer Disease: diagnostic imaging (MeSH) ; Alzheimer Disease: physiopathology (MeSH) ; Alzheimer Disease: metabolism (MeSH) ; Positron-Emission Tomography: methods (MeSH) ; Female (MeSH) ; Electroencephalography: methods (MeSH) ; Biomarkers: metabolism (MeSH) ; Male (MeSH) ; tau Proteins: cerebrospinal fluid (MeSH) ; Aged (MeSH) ; Cross-Sectional Studies (MeSH) ; Aged, 80 and over (MeSH) ; Brain: diagnostic imaging (MeSH) ; Brain: physiopathology (MeSH) ; Brain: metabolism (MeSH) ; Cohort Studies (MeSH) ; Amyloid beta-Peptides: metabolism (MeSH) ; AD biomarkers ; Alzheimer’s disease ; Electroencephalography ; Event-related potential ; PET-amyloid SUVR ; Regression modeling ; Biomarkers ; tau Proteins ; Amyloid beta-Peptides

---

Contributing Institute(s):

1. Vascular Cognitive Impairment & Post-Stroke Dementia (AG Dichgans)
2. Molecular Neurobiology (AG Simons)
3. Molecular Neurodegeneration (AG Haass)
4. Clinical Research (Munich) (Clinical Research (Munich))

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)
2. 351 - Brain Function (POF4-351) (POF4-351)
3. 352 - Disease Mechanisms (POF4-352) (POF4-352)

---

Database coverage:
; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---